St.shine Optical (1565) reported revenue of NT$281.4 million for Oct 2026, -11.5% year on year and -7.0% from the previous month. Revenue for Jan–Oct 2026 was NT$2.97 billion (-15.0% year on year).
In Oct 2026, it ranked No. 35 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$281.4 million | -11.5% | -7.0% |
| Sep 2026 | NT$302.6 million | -6.3% | +0.1% |
| Aug 2026 | NT$302.1 million | -12.5% | -0.4% |
| Jul 2026 | NT$303.4 million | -10.2% | +0.6% |
| Jun 2026 | NT$301.7 million | -16.8% | +9.6% |
| May 2026 | NT$275.3 million | -16.7% | -9.4% |
| Apr 2026 | NT$303.8 million | -16.6% | -0.4% |
| Mar 2026 | NT$305.1 million | -19.0% | +7.6% |
| Feb 2026 | NT$283.5 million | -29.7% | -8.8% |
| Jan 2026 | NT$311 million | -6.1% | -3.8% |
| Dec 2025 | NT$323.3 million | -23.3% | +7.2% |
| Nov 2025 | NT$301.4 million | -23.8% | -5.1% |
| Oct 2025 | NT$317.8 million | -23.1% | -1.6% |
| Sep 2025 | NT$323 million | -22.1% | -6.4% |
| Aug 2025 | NT$345.1 million | -14.2% | +2.2% |
| Jul 2025 | NT$337.8 million | -17.0% | -6.8% |
| Jun 2025 | NT$362.6 million | +12.2% | +9.7% |
| May 2025 | NT$330.5 million | -3.7% | -9.3% |
| Apr 2025 | NT$364.4 million | +10.4% | -3.3% |
| Mar 2025 | NT$376.9 million | -0.3% | -6.5% |
| Feb 2025 | NT$403 million | +27.9% | +21.7% |
| Jan 2025 | NT$331.1 million | -18.5% | -21.4% |
| Dec 2024 | NT$421.2 million | +10.5% | +6.5% |
| Nov 2024 | NT$395.6 million | +3.7% | -4.2% |
| Oct 2024 | NT$413.1 million | +11.1% | -0.4% |
Jan–Oct 2026 cumulative: NT$2.97 billion (-15.0% YoY)
Other Biotech & Medical companies
Compare with peers: St.shine Optical vs PEC / St.shine Optical vs Lotus Pharm / St.shine Optical vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16